← Patent-cliff monitor small molecule BREXAFEMME IBREXAFUNGERP CITRATE
Loss of exclusivity June 2039 latest FDA-listed patent expiry
Drug detail Brand name BREXAFEMME Active ingredient IBREXAFUNGERP CITRATE Strength EQ 150MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2021 Marketing status RX
Listed patents Patent Expires Type 11534433 June 2039 use U-3508 10370406 January 2035 use U-3159 10927142 January 2035 substance 10174074 January 2035 substance, product 8188085 August 2030 substance, product
Regulatory exclusivity Code Expires GAIN June 2031 NCE June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.